How much funding has S1P Therapeutics raised?

S1P Therapeutics has disclosed $2M raised across 1 round.

Where is S1P Therapeutics headquartered?

S1P Therapeutics is headquartered in Blacksburg, US.

S1P Therapeutics

Blacksburg, US · Founded 2019 · Delaware corporation

Find your way into S1P Therapeutics

67 people in our graph share verified history with the S1P Therapeutics team — schools, employers, funds. One of them is your warm intro.

Thomas Chamberlain, PharmDunlockedknows Kevin R. Lynch · together at University of Rhode Island (overlapped)

×3knows the team · via University of Rhode Island

×8knows the team · via Penn State University

S1P Therapeutics is a preclinical-stage biotechnology company developing drugs that target novel nodes in the S1P pathway for treating kidney and autoimmune diseases. Its aim is to create medicines with less toxicity than existing S1P pathway drugs.

Biotech Healthtech Longevity

Founders & leadership

Ron SaycoChief Executive Officer

Kevin R. Lynch Chief Scientific OfficerKevin Lynch is Chief Scientific Officer of S1P Therapeutics, where he focuses on developing compounds that modulate S1P pathway biology for therapeutic applications. His research background includes the study of sphingosine 1-phosphate signaling and discovery of pharmacological tools targeting S1P receptors and metabolic enzymes.

Webster SantosCo-Founder

Reported raises · per SEC filings

Form D private placements

$2M disclosed across 1 round · 2023

▶$2MraisedJun 2023 · 1 investors · Pharmaceuticals

Rule 506(b)

Officers, directors & promoters on the filing

Kevin LynchExecutive Officer, Director
Webster SantosExecutive Officer, Director
Ronald SaycoExecutive Officer, Director

Offering amount: $3M
Amount sold: $2M
First sale: May 2023
Incorporated: Corporation, Delaware, 2019
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Virginia Catalyst Awards $3.2 Million in Grants to Support Life Sciences in the Commonwealth | VirginiaBiovabio.org · Mar 2025

Frequently asked questions

What does S1P Therapeutics do?: S1P Therapeutics is a preclinical-stage biotechnology company developing drugs that target novel nodes in the S1P pathway for treating kidney and autoimmune diseases. Its aim is to create medicines with less toxicity than existing S1P pathway drugs.
How much funding has S1P Therapeutics raised?: S1P Therapeutics has disclosed $2M raised across 1 round.
Where is S1P Therapeutics headquartered?: S1P Therapeutics is headquartered in Blacksburg, US.